PECAM1 and cancer: EndMT is a process characterized by the downregulation of endothelial-specific markers such as CD31 and the upregulation of mesenchymal markers such as a-SMA, and EndMT occurs in a broad spectrum of conditions, including tissue fibrosis, cancer, heterotopic ossification and atherosclerosis42,43.